Consequently, we posit that alirocumab or statin administration holds promise in preventing lung fibrosis by suppressing pro-inflammatory cytokines, the RAS, the NLRP3 inflammasome, and subsequently, TGF-β1 signaling, independent of obesity. Here, TGFB1 is linked to pulmonary fibrosis.